Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 19/20 | 0.46 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.40 |
| ▸ | IRAK3 | Q9Y616 | 2/20 | 0.40 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21705185 | 0.86 | IRAK4 (0.48) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| SCHEMBL23425374 | 0.86 | IRAK4 (0.48) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| SCHEMBL21678751 | 0.86 | IRAK4 (0.48) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| SCHEMBL21701354 | 0.84 | IRAK4 (0.46) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| SCHEMBL23425377 | 0.79 | IRAK4 (0.47) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| SCHEMBL23425376 | 0.79 | IRAK4 (0.47) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| SCHEMBL21704953 | 0.79 | IRAK4 (0.45) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| Hydrochloric Acid SCHEMBL21678510 | 0.78 | IRAK4 (0.44) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| Hydrochloric Acid SCHEMBL21678507 | 0.78 | IRAK4 (0.44) | IRAK4IRAK1IRAK3IRAK2CLK1 | |
| SCHEMBL23425384 | 0.76 | IRAK4 (0.47) | IRAK4IRAK1IRAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ACLARIS THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048262-A1 | PYRROLOPYRIMIDINE ITK INHIBITORS | ITK, PDXK, DMPK | IRAK4 31/4885IRAK1 26/4885IRAK3 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.